🇺🇸 FDA

Intelligence Platform

Patents

Browse 763 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11452775

Detection of arginine methylation of EGFR for prediction of resistance to therapy

The Board of Regents of the University of Texas System · Granted Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11453719

Compositions and methods for treating cancer with anti-ROR1 immunotherapy

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11446397

Gene therapy vectors for treating heart disease

Tenaya Therapeutics, Inc. · Granted Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11446332

Combinatorial cancer immunotherapy

Senti Biosciences, Inc. · Granted Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11439632

Use of neuronal nitric oxide synthase inhibitors for immunotherapy in melanoma patients

Northwestern University · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11439683

Anti-angiogenic therapy of metastatic colorectal cancer

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11433131

Adoptive cell therapy using spherical nucleic acids (SNAs)

Northwestern University · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11433143

Nano-enabled immunotherapy in cancer

The Regents of the University of California · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11426385

Methods of improving cancer chemotherapy

THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS · Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11427646

Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis

B CELL DESIGN · Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11419898

Combinatorial cancer immunotherapy

Senti Biosciences, Inc. · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11421034

Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

Five Prime Therapeutics, Inc. · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11414489

Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor

HALOZYME, INC. · Granted Tue Aug 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11401506

Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy

Board nf Regents The Inivercitvof Texas Cvctom · Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11395838

Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome

The Board of Regents of the University of Texas System · Granted Tue Jul 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11397184

Selection of patients for combination therapy

Syndax Pharmaceuticals, Inc. · Granted Tue Jul 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11396647

Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy

The Board of Regents of the University of Texas System · Granted Tue Jul 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11389480

Human monoclonal antibody targeting TNFR2 for cancer immunotherapy

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11389481

Allogeneic cell therapy of B cell malignancies using genetically engineered T cells target

CRISPR THERAPEUTICS AG · Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11389432

Methods of treating cancer comprising administration of a glucocorticoid receptor modulato

Corcept Therapeutics Incorporated · Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11384337

Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses o

Iovance Biotherapeutics, Inc. · Granted Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11376324

Sting activating nanovaccine for immunotherapy

The Board of Regents of the University of Texas System · Granted Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11376247

Tyrosine kinase inhibitors regenerate non-cancerous tissue after cancer therapy

The Regents of the University of Colorado, a Body Corporate · Granted Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11365250

Compositions and methods for cancer therapy

The Board of Regents of the University of Texas System · Granted Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted